Overview

A Study of LY2940094 in Major Depressive Disorder

Status:
Completed

Trial end date:
2011-09-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the safety and tolerability of ascending single and multiple oral doses of LY2940094 in healthy male subjects.

Phase:

Phase 1

Details

Lead Sponsor:

BlackThorn Therapeutics, Inc.
Eli Lilly and Company